Physician profile
Kara M Sullivan
NPI 1922142975
$2,420.20
in general payments reported to CMS, 2019-2025
34 companies · $243 in 2025
The $243 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $145 · 2021: $156 · 2022: $223 · 2023: $465 · 2024: $986 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,671 · Education: $23.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,670.55 |
| Education | $23.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $654.02 | 2021-2024 | Zeposia |
| Abbvie INC. | $141.73 | 2020-2024 | Rinvoq |
| Ironwood Pharmaceuticals, INC | $136.20 | 2019-2024 | |
| Janssen Biotech, INC. | $126.43 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $113.31 | 2023-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $98.19 | 2019-2024 | Dificid |
| Qol Medical, LLC | $84.86 | 2019-2024 | Sucraid, Sucraid |
| Ucb, INC. | $79.05 | 2019-2020 | |
| Organon LLC | $76.80 | 2021-2023 | Hadlima |
| Daiichi Sankyo INC. | $69.67 | 2022-2024 | Injectafer |
| Romark Laboratories, Lc | $66.72 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $66.42 | 2022-2024 | Dupixent |
| Sandoz INC. | $60.66 | 2023-2024 | Hyrimoz |
| Takeda Pharmaceuticals U.S.A., INC. | $57.78 | 2020-2025 | Entyvio |
| Celltrion USA INC. | $57.45 | 2024-2025 | Vegzelma, Zymfentra |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $50.08 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $47.58 | 2024-2025 | Bylvay, Iqirvo |
| Gilead Sciences, INC. | $43.63 | 2019-2021 | |
| Pfizer INC. | $38.94 | 2021-2025 | |
| Pharmacosmos Therapeutics INC. | $35.80 | 2025 | Monoferric |
| Aimmune Therapeutics, INC. | $33.74 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $29.63 | 2022-2023 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $28.68 | 2022-2023 | |
| Fresenius Kabi USA, LLC | $27.98 | 2023-2024 | Idacio |
| Intercept Pharmaceuticals, INC. | $27.93 | 2024 | |
| Amgen INC. | $25.24 | 2023 | Amjevita, Avsola |
| Digestive Care, INC. | $24.85 | 2024 | Pertzye |
| Otsuka America Pharmaceutical, INC. | $19.13 | 2024 | Nuedexta |
| Ferring Pharmaceuticals INC. | $18.58 | 2023 | Rebyota |
| Mirum Pharmaceuticals, INC. | $17.59 | 2025 | Livmarli |
| Alfasigma USA, INC. | $17.39 | 2020 | |
| Neurelis, INC. | $15.82 | 2024 | Valtoco |
| Capsovision, INC. | $14.51 | 2024 | Capsocam Plus |
| Corium, LLC | $13.81 | 2024 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.